title: [Hereditary ovarian carcinomas: clinico-biological features and treatment].
abstract: Hereditary ovarian cancers account for 10% of all cases. Two major syndromes with dominant autosomal transmission are identified. The most common one is breast-ovarian cancer syndrome due to BRCA1 and BRCA2 genes mutations, and the Lynch syndrome with mutated MMR genes is the other. Alterations in homologous recombination specifically observed in ovarian cancer with BRCA defects associated to Parp inhibition create a synthetic lethality of special interest. Numerous studies are in progress to explore this promising new approach. Furthermore, it seems that carcinogenesis of these two syndromes are different, suggesting alternative therapeutic options in the near future in order to improve prognosis of ovarian carcinomas.
authors.affiliation: Institut Bergonié, département d'oncologie médicale, 229, cours de l'Argonne, 33076 Bordeaux cedex, France.
authors.forename: Anne
authors.initials: A
authors.lastname: Floquet
authors.affiliation: Institut Bergonié, département de chirurgie, 229, cours de l'Argonne, 33076 Bordeaux cedex, France.
authors.forename: Eberhard
authors.initials: E
authors.lastname: Stoeckle
authors.affiliation: Institut Bergonié, département d'anatomo-pathologie, 229, cours de l'Argonne, 33076 Bordeaux cedex, France.
authors.forename: Sabrina
authors.initials: S
authors.lastname: Croce
authors.affiliation: Institut Bergonié, unité d'oncogénétique, 229, cours de l'Argonne, 33076 Bordeaux cedex, France.
authors.forename: Michel
authors.initials: M
authors.lastname: Longy
authors.affiliation: Institut Bergonié, département d'anatomo-pathologie, 229, cours de l'Argonne, 33076 Bordeaux cedex, France.
authors.forename: Gaétan
authors.initials: G
authors.lastname: Mc Grogan
authors.affiliation: Institut Bergonié, unité d'oncogénétique, 229, cours de l'Argonne, 33076 Bordeaux cedex, France.
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Barouk
authors.affiliation: Institut Bergonié, unité d'oncogénétique, 229, cours de l'Argonne, 33076 Bordeaux cedex, France.
authors.forename: Virginie
authors.initials: V
authors.lastname: Bubien
authors.affiliation: Institut Bergonié, département d'oncologie médicale, 229, cours de l'Argonne, 33076 Bordeaux cedex, France.
authors.forename: Delphine
authors.initials: D
authors.lastname: Garbay
authors.affiliation: Institut Bergonié, unité d'oncogénétique, 229, cours de l'Argonne, 33076 Bordeaux cedex, France.
authors.forename: Eglantine
authors.initials: E
authors.lastname: Joly
authors.affiliation: Institut Bergonié, département de chirurgie, 229, cours de l'Argonne, 33076 Bordeaux cedex, France.
authors.forename: Frédéric
authors.initials: F
authors.lastname: Guyon
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D024682:BRCA2 Protein / Q000235:genetics; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D006801:Humans; D008875:Middle Aged; D009154:Mutation; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D010793:Phthalazines / Q000009:adverse effects / Q000627:therapeutic use*; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D000067856:Poly(ADP-ribose) Polymerase Inhibitors
chemical_list: D000970:Antineoplastic Agents; D024682:BRCA2 Protein; D010793:Phthalazines; D010879:Piperazines; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; C531550:olaparib
keywords: Lynch syndrom; Parp inhibitors; hereditary breast ovarian cancer; hereditary ovarian cancer
vernacular_title: Les formes héréditaires du cancer de l'ovaire : particularités clinico-biologiques et thérapeutiques.